<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="372854">
  <stage>Registered</stage>
  <submitdate>4/05/2017</submitdate>
  <approvaldate>22/05/2017</approvaldate>
  <actrnumber>ACTRN12617000752369</actrnumber>
  <trial_identification>
    <studytitle>Screening of alpha thalassemia disease in Dubai by using red cell volume in cord blood.</studytitle>
    <scientifictitle>Prevalence of a-Thalassemia syndromes in Dubai using red cell indices of neonatal cord blood.</scientifictitle>
    <utrn>                   is U1111-1196-2323</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Alpha Thalassemia</healthcondition>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Alpha Thalassemia is a hereditary blood disorder occurring due to genetic defect causing deficient synthesis of hemoglobin polypeptide chains. it occurs with significant frequency in the gulf area and middle east.
The purpose of this prospective  study is to evaluate the role of red blood cells indices mainly the mean corpuscular volume (MCV) as a screening tool for diagnosis of alpha thalassemia syndromes in UAE nationals born in Dubai hospital.
We will study the red blood cell indices namely the MCV, mean corpuscular hemoglobin (MCH) ,hemoglobin level  (Hb) , and Red cell distribution width (RDW)  from umbilical cord blood samples of all eligible neonates delivered in Dubai Hospital in the period from june 2017 till june 2018.
Hb electrophoresis will be carried on samples with low MCV less than 90 Fl. To evaluate the level of hemoglobin Barts .
All cases with positive hemoglobin Barts will be assigned for alpha thalassemia gene deletion detection by multiplex PCR method.
Umbilical cord blood samples will be collected by the registered obstetric nurse assigned in labour suit or operation theatre and data will be recorded by neonatology registrars using the designed study tool. Statistical analysis will be carried on by the end of the 12 month trial period.
</interventions>
    <comparator>no control group</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Early detection / Screening</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To assess the sensitivity of a low MCV on neonatal  cord blood samples  as a diagnostic tool of alpha thalassemia in Dubai  by comparison to Hb electrophoresis and multiplex PCR results on each sample with MCV less than 90 Fl.</outcome>
      <timepoint>at birth</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>prevalence of  neonatal alpha thalassemia syndrome in dubai by simultaneous testing of Hb electrophoresis, MCV, and multiplex PCR on neonatal cord blood samples.</outcome>
      <timepoint>at birth</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>All healthy neonates delivered at dubai hospital</inclusivecriteria>
    <inclusiveminage>1</inclusiveminage>
    <inclusiveminagetype>Hours</inclusiveminagetype>
    <inclusivemaxage>4</inclusivemaxage>
    <inclusivemaxagetype>Weeks</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>1- major congenital anomalies
2- inpatient neonates underwent exchange transfusion.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Diagnosis</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods>all infants born at dubai hospital during the study period will be enrolled in the trial 
Sample size will be determined by the end of the 12 month trial</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/06/2017</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate>1/06/2018</anticipatedenddate>
    <actualenddate />
    <samplesize>3000</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>6/06/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>United Arab Emirates</country>
      <state>Dubai</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>dubai hospital</primarysponsorname>
    <primarysponsoraddress>Dubai Hospital
Albaraha- Diera
AlKornisch streey number 1.
PO BOX 7272
Dubai</primarysponsoraddress>
    <primarysponsorcountry>United Arab Emirates</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>dubai hospital</fundingname>
      <fundingaddress>Dubai Hospital
Albaraha- Diera
AlKornisch streey number 1.
PO BOX 7272
Dubai</fundingaddress>
      <fundingcountry>United Arab Emirates</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Alpha thalassemia is a common hematologic disorder in the gulf area with devastating long term sequelae. our hypothesis is to test the sensitivity of  red blood cells indices mainly the mean corpuscular volume MCV as a screening test for an early diagnosis of the disease. All newborn infants delivered in Dubai hospital will be enrolled in the trial excluding infants with major congenital malformations. Full blood count will be carried on cord blood samples and cases with low MCV less than 90 fl are candidates for hemoglobin electrophoresis. Those with positive hemoglobin Bart will be examined for alpha thalassemia gene deletion detection by multiplex PCR method. These data will be recorded over 12 month period by neonatologists in NICU, Dubai hospital for statistical analysis at the end of the trial</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Dubai scientific research ethics committee DSREC</ethicname>
      <ethicaddress>Dubai Scientific Research Ethics Committee DSREC,
CONTINUOUS MEDICAL EDUCATION DEPARTMENT
RASHID MEDICAL LIBRARY
PO BOX 4545
DUBAI.
UAE</ethicaddress>
      <ethicapprovaldate>26/01/2017</ethicapprovaldate>
      <hrec>DSREC-10/2016-14</hrec>
      <ethicsubmitdate>21/11/2016</ethicsubmitdate>
      <ethiccountry>United Arab Emirates</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment>
    <filepath>http://www.anzctr.org.au/AnzctrAttachments/372854-DOC166.pdf</filepath>
  </attachment>
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Abdulrahman Al Jassimi</name>
      <address>Dubai Hospital
Albaraha, Diera
Alkornisch street number 1.
second floor, CEO office
PO BOX 7272
Dubai, UAE.</address>
      <phone>+971506511190</phone>
      <fax />
      <email>amAlJassmi@dha.gov.ae</email>
      <country>United Arab Emirates</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Mahmoud Galal Mahmoud Ahmed</name>
      <address>Dubai Hospital
NICU, third floor
Albaraha, Diera, AlKornisch street number 1.
PO BOX 7272
Dubai, UAE.</address>
      <phone>+971501879895</phone>
      <fax />
      <email>MMahmoudahmed@dha.gov.ae</email>
      <country>United Arab Emirates</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>ATEF ALSHAFEI</name>
      <address>Dubai Hospital
NICU, third floor
Albaraha, Diera, AlKornisch street number 1.
PO BOX 7272
Dubai, UAE.</address>
      <phone>+971561924270</phone>
      <fax />
      <email>ahalshafei@dha.gov.ae</email>
      <country>United Arab Emirates</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>ATEF ALSHAFEI</name>
      <address>Dubai Hospital
NICU, third floor
Albaraha, Diera, AlKornisch street number 1.
PO BOX 7272
Dubai, UAE.</address>
      <phone>+97142195000</phone>
      <fax />
      <email>ahalshafei@dha.gov.ae</email>
      <country>United Arab Emirates</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>